TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib
Wang, Wen-Xian, Xu, Chun-Wei, Chen, Yan-Ping, Liu, Wei, Zhong, Li-Hua, Chen, Fang-Fang, Zhuang, Wu, Huang, Yun-Jian, Huang, Zhang-Zhou, Chen, Rong-Rong, Guan, Yan-Fang, Yi, Xin, Lv, Tang-Feng, Zhu, WeТом:
10
Мова:
english
Журнал:
Journal of Thoracic Disease
DOI:
10.21037/jtd.2018.04.98
Date:
May, 2018
Файл:
PDF, 1.39 MB
english, 2018
File converter
Більше результатів пошуку
More benefits 
